Alpha9 Theranostics
Alpha-9 Oncology is a clinical-stage biotechnology company pioneering radiopharmaceutical innovation for solid tumors. Our proprietary scaffolds, composed of optimized binders, linkers, chelators, and radioisotopes, enable targeted radiation delivery to cancer cells, minimizing harm to surrounding healthy tissue. Focusing on innovative targeting moieties, we develop molecules tailored for precise tumor targeting. Our comprehensive platform integrates imaging and therapeutic studies to ensure effective radiation delivery and improved patient outcomes. With a robust pipeline entering clinical trials and strong support from leading healthcare investors, Alpha-9 is positioned for rapid growth and advancement in cancer therapy.
Industries
Nr. of Employees
small (1-50)
Alpha9 Theranostics
Products
Gallium-68 PET diagnostic targeting melanocortin 1 receptor (MC1R)
A PET diagnostic agent labeled with gallium-68 designed to image MC1R-expressing melanoma to support patient selection and dosimetry assessment.
Gallium-68 PET diagnostic targeting melanocortin 1 receptor (MC1R)
A PET diagnostic agent labeled with gallium-68 designed to image MC1R-expressing melanoma to support patient selection and dosimetry assessment.
Services
End-to-end platform covering target selection, binder and linker design, radiochemistry, formulation, preclinical in vitro/in vivo evaluation, analytical method development, and early-phase clinical translation.
End-to-end platform covering target selection, binder and linker design, radiochemistry, formulation, preclinical in vitro/in vivo evaluation, analytical method development, and early-phase clinical translation.
Expertise Areas
- Radiopharmaceutical design and discovery
- Radiochemistry and radiolabeling for alpha, beta and PET emitters
- Preclinical translational biology and in vivo pharmacology
- Clinical trial design and execution for imaging and radiotherapeutics
Key Technologies
- Actinium-225 therapeutic alpha emitters
- Lutetium-177 therapeutic beta emitters
- Gallium-68 and Fluorine-18 PET radiochemistry
- PET and SPECT clinical imaging
News & Updates
ITM will supply Actinium-225 to support Alpha-9’s radiopharmaceutical programs, enabling precise tumor targeting with alpha particles.
Alpha-9 raised $175M to fund clinical trials and expand its pipeline of targeted radiopharmaceuticals for cancer treatment.
Leadership additions to guide the company's growth in radiopharmaceutical development.
Alpha-9's radiodiagnostic targeting MC1R for melanoma imaging and potential therapy.
Funding to advance five candidates into the clinic and expand discovery programs.
Partnership to supply Lutetium-177 for radiopharmaceutical development.
ITM will supply Actinium-225 to support Alpha-9’s radiopharmaceutical programs, enabling precise tumor targeting with alpha particles.
Alpha-9 raised $175M to fund clinical trials and expand its pipeline of targeted radiopharmaceuticals for cancer treatment.
Leadership additions to guide the company's growth in radiopharmaceutical development.
Alpha-9's radiodiagnostic targeting MC1R for melanoma imaging and potential therapy.
Funding to advance five candidates into the clinic and expand discovery programs.
Partnership to supply Lutetium-177 for radiopharmaceutical development.